An SSRI begins blocking serotonin reuptake within hours of the first dose, yet a patient shows no improvement in depression for 4–6 weeks. What best explains this delay?
ASSRIs have poor bioavailability and require weeks of accumulation before reaching therapeutic plasma levels
BSerotonin reuptake blockade alone is insufficient — clinical improvement requires gradual neuroadaptation: autoreceptor desensitization, changes in receptor expression, and BDNF-mediated neuroplasticity that accumulate over weeks of sustained elevated signaling
CThe delay is a placebo effect; the medication itself works immediately but patients take time to notice
DThe liver needs several weeks to convert SSRIs into their active metabolites
Reuptake blockade increases synaptic serotonin within hours — this is pharmacologically confirmed. But autoreceptors (especially 5-HT1A) initially dampen this effect by reducing neuronal firing. Over weeks, these autoreceptors desensitize, and downstream changes in receptor expression and neuroplasticity markers like BDNF accumulate. Clinical antidepressant effect correlates with these longer-timescale neuroadaptations, not with the initial reuptake block. This is why stopping medication prematurely is a major cause of treatment failure.
Question 2 Multiple Choice
A patient with major depressive disorder is prescribed a standard SSRI at therapeutic dose. After 6 weeks of consistent use, they report no improvement. What does this most likely reflect?
AThe patient has not been taking the medication correctly — non-compliance is the only reason SSRIs fail
BSSRIs are effective for anxiety but not for depression — a different drug class is needed
CNon-response is expected in roughly 40% of patients on first-line treatment; individual variation in biology, genetics, and depression subtype means not everyone responds to any given agent
DThe dose is certainly too low — first-line SSRIs always work if the dose is sufficient
The ~60% response rate for antidepressants means approximately 40% of patients do not respond to a first-line agent. This non-response is not primarily explained by non-compliance or insufficient dosing — it reflects genuine biological heterogeneity: variation in which monoamine systems are dysregulated, in CYP450 enzyme genetics that affects drug metabolism, and in depression subtypes. Treatment-resistant depression requires escalating strategies including medication switches, augmentation, or non-pharmacological interventions.
Question 3 True / False
Despite differing greatly in mechanism — SSRIs block SERT selectively, MAOIs prevent monoamine degradation entirely, and tricyclics block multiple transporters and receptors — all major antidepressant classes show roughly comparable overall efficacy in treating MDD.
TTrue
FFalse
Answer: True
True — this is one of the most clinically important and theoretically puzzling findings in psychopharmacology. Across controlled trials, all major antidepressant classes achieve response rates of approximately 60% in MDD, despite targeting monoamine systems through very different mechanisms. This convergent efficacy suggests that what matters for antidepressant effect is sustained upregulation of monoaminergic tone and resulting neuroadaptation, rather than the specific mechanism by which monoamine levels are increased.
Question 4 True / False
SSRIs work by increasing serotonin production in the presynaptic neuron.
TTrue
FFalse
Answer: False
False — SSRIs do not affect serotonin synthesis or production. They block the serotonin transporter (SERT), which is responsible for reuptaking serotonin from the synapse back into the presynaptic neuron. Blocking SERT leaves more serotonin in the synapse for longer, increasing its availability for postsynaptic receptors. Serotonin is still synthesized from tryptophan via the same pathway as before; the SSRI only affects how quickly it is removed from the synaptic cleft.
Question 5 Short Answer
Explain why the 4–6 week delay in antidepressant effect is clinically important and what it implies about the mechanism by which antidepressants relieve depression.
Think about your answer, then reveal below.
Model answer: Clinically, the delay matters because patients and clinicians need to know that early absence of improvement does not mean the medication isn't working — stopping too soon is a leading cause of treatment failure. It also means patients need monitoring for side effects or worsening during the lag period. Mechanistically, the delay implies that simple reuptake blockade (which happens within hours) is not the final therapeutic step. Instead, the antidepressant effect depends on slower neuroadaptive processes: autoreceptors that initially blunt the serotonergic increase gradually desensitize, receptor expression changes, and neuroplasticity-related proteins like BDNF require weeks of sustained elevated signaling to accumulate to therapeutically meaningful levels.
The 4–6 week timeline aligns with the time course of synaptic plasticity and receptor regulation, not pharmacokinetics. This has driven theories that depression involves impaired neuroplasticity (not just monoamine deficiency), and it is why newer fast-acting treatments like ketamine (which works within hours through NMDA receptor antagonism and rapid BDNF release) are so significant — they decouple antidepressant effect from the slow neuroadaptation timeline.